scholarly journals Roles of NOTCH1 as a Therapeutic Target and a Biomarker for Lung Cancer: Controversies and Perspectives

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Lixia Guo ◽  
Ting Zhang ◽  
Ying Xiong ◽  
Yanan Yang
Keyword(s):  
Lung Cancer ◽  
Therapeutic Target ◽  
Early Stage ◽  
Small Population ◽  
Cancer Development ◽  
Potential Usefulness ◽  
Early Stage Lung Cancer ◽  
Human Carcinogenesis ◽  
Stage Lung Cancer

Lung cancer is one of the most common types of human malignancies and the leading cause of cancer-related death. Patients with surgically resectable early stage lung cancer are more likely curable, but currently only a small population of patients can be diagnosed at such a stage, partly due to our incomplete understanding of the biology of lung cancer and the lack of diagnostic and prognostic biomarkers. Recent studies have shown that NOTCH1 is a critical regulator of human carcinogenesis and has been implicated in multiple steps of cancer development and progression. Herein, we review recent findings about the role of NOTCH1 in lung cancer and discuss its potential usefulness as both a therapeutic target and a biomarker for lung cancer.

scholarly journals A review of the role of MRI in diagnosis and treatment of early stage lung cancer

2020 ◽  
Vol 24 ◽  
pp. 16-22 ◽  
Author(s):  
Austin J. Sim ◽  
Evangelia Kaza ◽  
Lisa Singer ◽  
Stephen A. Rosenberg
Keyword(s):  
Lung Cancer ◽  
Early Stage ◽  
Diagnosis And Treatment ◽  
Early Stage Lung Cancer ◽  
Stage Lung Cancer

PD-1 Blockade in Early-Stage Lung Cancer

2019 ◽  
Vol 70 (1) ◽  
pp. 425-435 ◽  
Author(s):  
Samuel Rosner ◽  
Joshua E. Reuss ◽  
Patrick M. Forde
Keyword(s):  
Lung Cancer ◽  
Early Stage ◽  
Immune Checkpoint Blockade ◽  
Advanced Lung Cancer ◽  
Early Stage Lung Cancer ◽  
Early Results ◽  
Stage Disease ◽  
Relapse Rates ◽  
Stage Lung Cancer

Early-stage non–small cell lung cancer is a potentially curable disease, but with relapse rates exceeding 50% with standard treatments, this is a patient population in critical need of therapy innovation. Immunotherapy with immune checkpoint blockade has revolutionized the treatment strategy for advanced lung cancer. However, the role of this therapy in earlier-stage disease is largely unknown. The study of immunotherapy in earlier-stage disease has many advantages, including assessment of pathologic response and incorporation of translational scientific analyses to evaluate antitumor immune responses. Multiple clinical trials are currently under way, with promising early results.

206 The role of VATS segmentectomy for early stage lung cancer

Lung Cancer ◽  
2014 ◽  
Vol 83 ◽  
pp. S76 ◽  
Author(s):  
M. Will ◽  
R. Ramaesh ◽  
D. Smith ◽  
W.S. Walker
Keyword(s):  
Lung Cancer ◽  
Early Stage ◽  
Early Stage Lung Cancer ◽  
Stage Lung Cancer

scholarly journals Deciphering the Immune–Tumor Interplay During Early-Stage Lung Cancer Development via Single-Cell Technology

2022 ◽  
Vol 11 ◽  
Author(s):  
Wei-Wei Chen ◽  
Wei Liu ◽  
Yingze Li ◽  
Jun Wang ◽  
Yijiu Ren ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Immune Response ◽  
Immune System ◽  
Single Cell ◽  
Early Stage ◽  
Current Understanding ◽  
Cancer Development ◽  
Early Stage Lung Cancer ◽  
Cell Technology ◽  
Stage Lung Cancer

Lung cancer is the leading cause of cancer-related death worldwide. Cancer immunotherapy has shown great success in treating advanced-stage lung cancer but has yet been used to treat early-stage lung cancer, mostly due to lack of understanding of the tumor immune microenvironment in early-stage lung cancer. The immune system could both constrain and promote tumorigenesis in a process termed immune editing that can be divided into three phases, namely, elimination, equilibrium, and escape. Current understanding of the immune response toward tumor is mainly on the “escape” phase when the tumor is clinically detectable. The detailed mechanism by which tumor progenitor lesions was modulated by the immune system during early stage of lung cancer development remains elusive. The advent of single-cell sequencing technology enables tumor immunologists to address those fundamental questions. In this perspective, we will summarize our current understanding and big gaps about the immune response during early lung tumorigenesis. We will then present the state of the art of single-cell technology and then envision how single-cell technology could be used to address those questions. Advances in the understanding of the immune response and its dynamics during malignant transformation of pre-malignant lesion will shed light on how malignant cells interact with the immune system and evolve under immune selection. Such knowledge could then contribute to the development of precision and early intervention strategies toward lung malignancy.

Sign in / Sign up

Export Citation Format

Share Document